CA2168211A1 - Method of preventing neutrophil mediated connective tissue damage - Google Patents
Method of preventing neutrophil mediated connective tissue damageInfo
- Publication number
- CA2168211A1 CA2168211A1 CA002168211A CA2168211A CA2168211A1 CA 2168211 A1 CA2168211 A1 CA 2168211A1 CA 002168211 A CA002168211 A CA 002168211A CA 2168211 A CA2168211 A CA 2168211A CA 2168211 A1 CA2168211 A1 CA 2168211A1
- Authority
- CA
- Canada
- Prior art keywords
- elastase
- cathepsin
- tissue degradation
- connective tissue
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002808 connective tissue Anatomy 0.000 title claims abstract description 24
- 210000000440 neutrophil Anatomy 0.000 title claims description 41
- 230000000451 tissue damage Effects 0.000 title abstract description 6
- 231100000827 tissue damage Toxicity 0.000 title abstract description 6
- 230000001404 mediated effect Effects 0.000 title description 9
- 238000000034 method Methods 0.000 title description 8
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 41
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 33
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 31
- 102000004173 Cathepsin G Human genes 0.000 claims description 31
- 108090000617 Cathepsin G Proteins 0.000 claims description 30
- 230000008354 tissue degradation Effects 0.000 claims description 13
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 12
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 12
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 12
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 12
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 9
- 206010014561 Emphysema Diseases 0.000 claims description 9
- 206010003246 arthritis Diseases 0.000 claims description 8
- 206010006451 bronchitis Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 210000000845 cartilage Anatomy 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 6
- 108010067787 Proteoglycans Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- MBOIJWCUNPHWQG-UHFFFAOYSA-N 3,4-diamino-6-phenylbenzene-1,2-disulfonic acid Chemical compound OS(=O)(=O)C1=C(N)C(N)=CC(C=2C=CC=CC=2)=C1S(O)(=O)=O MBOIJWCUNPHWQG-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 108010028275 Leukocyte Elastase Proteins 0.000 description 4
- 102000016799 Leukocyte elastase Human genes 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102000055008 Matrilin Proteins Human genes 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 102000052502 human ELANE Human genes 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000052896 human CTSG Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10555793A | 1993-08-12 | 1993-08-12 | |
| US08/105,557 | 1993-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2168211A1 true CA2168211A1 (en) | 1995-02-23 |
Family
ID=22306496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002168211A Abandoned CA2168211A1 (en) | 1993-08-12 | 1994-07-11 | Method of preventing neutrophil mediated connective tissue damage |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5384119A (en:Method) |
| EP (1) | EP0713394A1 (en:Method) |
| JP (1) | JPH09500903A (en:Method) |
| KR (1) | KR960703608A (en:Method) |
| CN (1) | CN1128952A (en:Method) |
| AU (1) | AU680284B2 (en:Method) |
| CA (1) | CA2168211A1 (en:Method) |
| HU (1) | HUT74581A (en:Method) |
| IL (1) | IL110616A0 (en:Method) |
| NO (1) | NO960550D0 (en:Method) |
| TW (1) | TW285641B (en:Method) |
| WO (1) | WO1995005185A1 (en:Method) |
| ZA (1) | ZA945938B (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2833744A (en) * | 1953-08-27 | 1958-05-06 | Ciba Pharm Prod Inc | Polyureas and process of preparing same |
| GB781479A (en) * | 1953-08-27 | 1957-08-21 | Ciba Ltd | New polyureas and process for making them |
| DE1067212B (de) * | 1956-06-04 | 1959-10-15 | Farbenfabriken Bayer Aktiengesellschaft, Leverkusen-Bayerwerk | Verfahren zur Herstellung von löslichen Polyharnstoffen |
| US3164571A (en) * | 1959-12-31 | 1965-01-05 | Union Carbide Corp | Polyureas from n-phenyl, phenylene biscarbamyl halide and a diamine |
| US3528949A (en) * | 1968-05-07 | 1970-09-15 | Atlas Chem Ind | Polymers from ureas and dihalides |
| DE2162963C3 (de) * | 1971-12-18 | 1979-02-01 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 1,4-Diaminobenzol-2,5-disulfonsäure |
| US3993625A (en) * | 1973-05-28 | 1976-11-23 | Toray Industries, Inc. | Permselective polymeric membranes of organic polyamide or polyhydrazide |
| US3978024A (en) * | 1973-12-28 | 1976-08-31 | General Electric Company | Flame retardant polycarbonate composition |
| DE2516305A1 (de) * | 1975-04-15 | 1976-10-28 | Dynamit Nobel Ag | Wasserdispergierbare esterharze |
| US4027038A (en) * | 1976-05-10 | 1977-05-31 | American Cyanamid Company | Complement inhibitors |
| US4087548A (en) * | 1976-05-10 | 1978-05-02 | American Cyanamid Company | Complement inhibitors |
| US4071524A (en) * | 1976-11-08 | 1978-01-31 | Riker Laboratories, Inc. | Derivatives of urea |
| JPH0140026B2 (en:Method) * | 1978-07-03 | 1989-08-24 | Amerikan Hoomu Purodakutsu Corp | |
| DE3026575A1 (de) * | 1980-07-12 | 1982-02-04 | Bayer Ag, 5090 Leverkusen | Antitumoral wirkende mittel |
| US4724235A (en) * | 1981-05-20 | 1988-02-09 | A. H. Robins Company, Incorporated | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia |
| US4471110A (en) * | 1982-08-02 | 1984-09-11 | E. I. Dupont De Nemours And Company | Polyamide of disulfonated diamine and permselective membrane thereof |
| DE3345902A1 (de) * | 1983-12-20 | 1985-08-29 | Cassella Ag, 6000 Frankfurt | In wasser loesliche polymischester, verfahren zu ihrer herstellung und ihre verwendung |
| US4824916A (en) * | 1985-03-15 | 1989-04-25 | The Dow Chemical Company | Water-insoluble, crosslinked, sulfonated aromatic polyamide |
| US4604404A (en) * | 1985-04-03 | 1986-08-05 | A. H. Robins Company, Inc. | Antiviral sulfonated naphthalene formaldehyde condensation polymers |
| FR2584606A1 (fr) * | 1985-07-12 | 1987-01-16 | Dropic | Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif |
| US4895660A (en) * | 1986-07-14 | 1990-01-23 | The Dow Chemical Company | Water-soluble aromatic polyamides and polyureas |
| GB9014546D0 (en) * | 1990-06-29 | 1990-08-22 | Fujisawa Pharmaceutical Co | Ws7622a mono-or di-sulfate,process for preparation thereof and use thereof |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
-
1993
- 1993-10-29 US US08/146,833 patent/US5384119A/en not_active Expired - Fee Related
-
1994
- 1994-07-11 HU HU9600305A patent/HUT74581A/hu unknown
- 1994-07-11 CN CN94193029A patent/CN1128952A/zh active Pending
- 1994-07-11 AU AU73586/94A patent/AU680284B2/en not_active Ceased
- 1994-07-11 EP EP94922509A patent/EP0713394A1/en not_active Withdrawn
- 1994-07-11 JP JP7506946A patent/JPH09500903A/ja active Pending
- 1994-07-11 KR KR1019960700672A patent/KR960703608A/ko not_active Withdrawn
- 1994-07-11 CA CA002168211A patent/CA2168211A1/en not_active Abandoned
- 1994-07-11 WO PCT/US1994/007696 patent/WO1995005185A1/en not_active Ceased
- 1994-08-08 ZA ZA945938A patent/ZA945938B/xx unknown
- 1994-08-09 TW TW083107251A patent/TW285641B/zh active
- 1994-08-10 IL IL11061694A patent/IL110616A0/xx unknown
-
1996
- 1996-02-12 NO NO960550A patent/NO960550D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7358694A (en) | 1995-03-14 |
| ZA945938B (en) | 1995-03-16 |
| JPH09500903A (ja) | 1997-01-28 |
| NO960550L (no) | 1996-02-12 |
| IL110616A0 (en) | 1994-11-11 |
| HU9600305D0 (en) | 1996-04-29 |
| CN1128952A (zh) | 1996-08-14 |
| AU680284B2 (en) | 1997-07-24 |
| US5384119A (en) | 1995-01-24 |
| WO1995005185A1 (en) | 1995-02-23 |
| HUT74581A (en) | 1997-01-28 |
| EP0713394A1 (en) | 1996-05-29 |
| TW285641B (en:Method) | 1996-09-11 |
| NO960550D0 (no) | 1996-02-12 |
| KR960703608A (ko) | 1996-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0692970B1 (en) | Use of actin-binding compounds for the manufacture of a medicament for reducing the viscosity of pathological mucoid airway contents in the respiratory tract | |
| Wuillemin et al. | Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. | |
| Ruiz-Torres et al. | Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies | |
| Wu et al. | Morin: a wood pigment that protects three types of human cells in the cardiovascular system against oxyradical damage | |
| CA2080462C (en) | Therapeutic uses of actin-binding compounds | |
| KR102753401B1 (ko) | 세포외 히스톤 매개된 병리를 치료 및 예방하기 위한 화합물 | |
| JPH04504710A (ja) | 抗血栓組成物 | |
| JPS6218401A (ja) | 結合組織病理において有効な医薬の製造に使用する多糖およびオリゴ糖 | |
| JP2005519914A (ja) | 結合組織の治療、防御および回復のためのニュートラシューティカルズ（ｎｕｔｒａｃｅｕｔｉｃａｌｓ） | |
| Levi et al. | Plasma and plasma components in the management of disseminated intravascular coagulation | |
| Kowanko et al. | Mechanisms of human neutrophil‐mediated cartilage damage in vitro: the role of lysosomal enzymes, hydrogen peroxide and hypochlorous acid | |
| Uchiba et al. | Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity | |
| US5384119A (en) | Method of preventing neutrophil mediated connective tissue damage | |
| Knight et al. | Neutral protease inhibitors from human intervertebral disc and femoral head articular cartilage | |
| Martorana et al. | Effect of human alpha1-antitrypsin on papain-induced emphysema in the hamster | |
| EP0651645B1 (en) | Medicament for inhibiting neutrophil elastase and cathepsin g | |
| Janusz et al. | Inhibition of human neutrophil elastase and cathepsin G by a diphenyl disulfonic acid copolymer | |
| Neubauer et al. | Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat | |
| RU2233171C2 (ru) | ПОЛИФУНКЦИОНАЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ L-ЛИЗИН-α-ОКСИДАЗЫ ИЗ ГРИБА РОДА TRICHODERMA И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО ФЕРМЕНТА | |
| Yamazaki et al. | Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats | |
| Okamoto et al. | Variation in activities of non-plasmin fibrinolytic proteinase and plasminogen-activator in the lung and spleen induced by bacterial endotoxin in rats with special reference to the effects of MD-805 | |
| Barisoni et al. | Monitoring of elastase in plasma of burned patients in relation to other inflammation parameters | |
| JP3761914B2 (ja) | アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤 | |
| Yagi et al. | Serum granulocytic elastase and superoxide dismutase activity after administration of protease-inhibitor to postoperative patients | |
| Wuillemin et al. | Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19990712 |